

CORRELATION ANALYSIS OF SERUM FGF9, SESTRIN2 AND HBDH WITH THE SEVERITY OF SEPSIS**ANALIZA KORELACIJE SERUMSKIH NIVOVA FGF9, SESTRINA2 I HBDH SA TEŽINOM SEPSE**Jian He^{1,2}, Xinru Lin³, Xiang Ding³, Maoxia Liu⁴¹Department of Emergency Medicine, Taikang Xianlin Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210033, China²Department of Emergency Medicine, Taikang Xianlin Drum Tower Hospital Clinical College of Wuhan University, Nanjing 210033, China³Department of Infectious Diseases, the Second Affiliated Hospital of Anhui Medical University, No. 678, Furong Road, Economic and Technological Development Zone, Hefei City 230601, China⁴Clinical Nutrition Department, Chongqing University Central Hospital (Chongqing Emergency Medical Centre), No. 1, Jiankang Road, Yuzhong District, Chongqing 400010, China**Summary**

Background: To explore the correlation between serum fibroblast growth factor 9 (FGF9), Sestrin2 and hydroxybutyrate dehydrogenase (HBDH) and the severity of sepsis, and to analyse the predictive value of FGF9, Sestrin2 and HBDH for clinical outcome.

Methods: A retrospective analysis of 125 patients with sepsis admitted to Taikang Xianlin Drum Tower Hospital and Chongqing University Central Hospital between May 2022 and May 2025 was conducted. According to disease severity, there were 50 cases in the septic shock group and 75 in the sepsis group. Based on clinical outcomes, patients were divided into a death group (103 cases) and a survival group (22 cases). Observe the levels of serum FGF9, Sestrin2 and HBDH in each group. Analysis of the relationships among FGF9, Sestrin2, HBDH, and sepsis severity was performed using the Spearman correlation coefficient. Using multivariate logistic regression analysis, the factors influencing the prognosis of patients with sepsis were investigated. FGF9, Sestrin2, and HBDH were evaluated for their prognostic utility in sepsis patients using receiver operating characteristic (ROC) curves.

Results: Compared with the sepsis group, the level of FGF9 in the septic shock group was lower [(122.41±21.45) pg/mL vs (145.36±23.68) pg/mL], while the levels of Sestrin2 and HBDH were both higher [(15.75±2.34) ng/mL] vs (8.36±0.93) ng/mL, (232.14±34.77) U/L vs (166.25±24.85) U/L]; the differences were statistically

Kratak sadržaj

Uvod: Cilj je bio da se istraži korelacija između serumskog faktora rasta fibroblasta 9 (FGF9), Sestrina2 i hidroksibutirat dehidrogenaze (HBDH) sa težinom sepse, i analizira prediktivna vrednost FGF9, Sestrina2 i HBDH u odnosu na klinički ishod.

Metode: Sprovedena je retrospektivna analiza koja je uključila 125 pacijenata sa sepsom primljenih u Taikang Xianlin Drum Tower bolnicu i Centralnu bolnicu Univerziteta u Chongqingu u periodu od maja 2022. do maja 2025. godine. Prema težini bolesti, bilo je 50 slučajeva u grupi sa septičkim šokom i 75 u grupi sa sepsom. Na osnovu kliničkih ishoda, pacijenti su podeljeni u grupu sa smrtnim ishodom (103 slučaja) i grupu preživelih (22 slučaja). Posmatrani su nivoi serumskog FGF9, Sestrina2 i HBDH u svakoj grupi. Analiza odnosa između FGF9, Sestrina2, HBDH i težine sepse sprovedena je korišćenjem Spirmanovog koeficijenta korelacije. Faktori koji utiču na prognozu pacijenata sa sepsom ispitani su multivarijantnom logističkom regresijom. Prognoistička vrednost FGF9, Sestrina2 i HBDH procenjena je pomoću ROC krivih.

Rezultati: U poređenju sa grupom sa sepsom, nivo FGF9 u grupi sa septičkim šokom bio je niži [(122,41±21,45) pg/mL vs (145,36±23,68) pg/mL], dok su nivoi Sestrina2 i HBDH bili viši [(15,75±2,34) ng/mL vs (8,36±0,93) ng/mL, (232,14±34,77) U/L vs (166,25±24,85) U/L]; razlike su bile statistički značajne (P<0,05). U poređenju

Address for correspondence:

Maoxia Liu
Clinical Nutrition Department, Chongqing University
Central Hospital (Chongqing Emergency Medical Centre)
No. 1, Jiankang Road, Yuzhong District, Chongqing
400010, China
e-mail: lmx_99410@163.com

significant ($P < 0.05$). Compared with the survival group, the level of FGF9 in the death group was lower [(112.05 ± 20.61) pg/mL vs (133.25 ± 22.14) pg/mL], while the levels of Sestrin2 and HBDH were both higher [(19.25 ± 2.85) ng/mL vs (12.42 ± 2.33) ng/mL, (261.25 ± 37.25) U/L vs (204.25 ± 32.18) U/L]. Spearman correlation coefficient analysis showed that FGF9 was negatively correlated with the severity of sepsis ($P < 0.05$), whereas the degree of sepsis was positively correlated with both Sestrin2 and HBDH ($P < 0.05$). Sequential Organ Failure Assessment (SOFA), Acute Physiology and Chronic Health Evaluation II (APACHE II), procalcitonin, FGF9, Sestrin2, and HBDH are risk factors for sepsis prognosis, according to multivariate logistic regression analysis ($P < 0.05$). The results of ROC curve analysis showed that the combined detection of FGF9, Sestrin2 and HBDH had a better predictive effect on the prognosis of patients with sepsis ($P < 0.05$).

Conclusions: The amount of FGF9 in septic shock patients is comparatively low, while the levels of Sestrin2 and HBDH are relatively high. As the severity of the disease increases, the level of FGF9 gradually decreases, while the levels of Sestrin2 and HBDH gradually increase, with a certain correlation with disease severity. The prognosis of sepsis patients can be assessed by measuring FGF9, Sestrin2, and HBDH levels.

Keywords: sepsis, fibroblast growth factor 9, Sestrin2, hydroxybutyrate dehydrogenase, correlation analysis

Introduction

A systemic inflammatory reaction condition brought on by an infection called sepsis, with a relatively high clinical mortality rate, which can pose a significant threat to patients' lives and safety (1–3). With the increase in the number of clinically obese and diabetic patients, the drug resistance of pathogenic bacteria is gradually rising, which can affect the treatment effect of sepsis patients (4). Consequently, patients' prognoses can be improved and the clinical treatment rate raised by early intervention to avert septic shock. Fibroblast growth factor-9 (FGF9) is an inflammation-related growth factor that can regulate various inflammatory diseases, inhibit the occurrence of sepsis, and reduce inflammatory infiltration of the alveolar wall. The stress-induced protein Sestrin2 can regulate inflammatory and stress responses within the body, causing autophagy in cells (5–7). An increase in Sestrin2 levels can promote the development of septic shock. Hydroxybutyrate dehydrogenase (HBDH) is mainly distributed in myocardial cells (8–10). After myocardial cells are damaged, the level of HBDH can increase, leading to myocardial injury in patients with sepsis and increasing the incidence of clinical death.

Sepsis is a systemic inflammatory response to infection. In clinical practice, it is a prevalent catastrophic illness, with a high incidence and mortality rate (11–13). Early identification of sepsis severity and timely adoption of effective treatment measures are crucial for improving patient prognosis. However, the

sa grupom preživelih, nivo FGF9 u grupi sa smrtnim ishodom je bio niži [$(112,05 \pm 20,61)$ pg/mL vs $(133,25 \pm 22,14)$ pg/mL], dok su nivoi Sestrina2 i HBDH bili viši [$(19,25 \pm 2,85)$ ng/mL vs $(12,42 \pm 2,33)$ ng/mL, $(261,25 \pm 37,25)$ U/L vs $(204,25 \pm 32,18)$ U/L]. Analiza Spearmanovog koeficijenta korelacije pokazala je da je FGF9 negativno korelisao sa težinom sepse ($P < 0,05$), dok je stepen sepse bio pozitivno korelisao sa Sestrinom2 i HBDH ($P < 0,05$). Multivarijatna logistička regresija pokazala je da SOFA (Sequential Organ Failure Assessment), APACHE II (Acute Physiology and Chronic Health Evaluation II), procalcitonin, FGF9, Sestrin2 i HBDH predstavljaju faktore rizika za prognozu sepse ($P < 0,05$). Rezultati ROC analize su pokazali da kombinovano određivanje FGF9, Sestrina2 i HBDH ima bolju prediktivnu vrednost za prognozu pacijenata sa sepsom ($P < 0,05$).

Zaključak: Količina FGF9 kod pacijenata sa septičkim šokom je relativno niska, dok su nivoi Sestrina2 i HBDH relativno visoki. Kako težina bolesti raste, nivo FGF9 postepeno opada, dok nivoi Sestrina2 i HBDH postepeno rastu, pri čemu postoji određena korelacija sa težinom bolesti. Prognoza u slučaju pacijenata sa sepsom se može odrediti merenjem nivoa FGF9, Sestrina2 i HBDH.

Ključne reči: sepsa, faktor rasta fibroblasta 9, Sestrin2, hidroksibutirat dehidrogenaza, analiza korelacije

commonly used sepsis assessment indicators in clinical practice at present, such as the SOFA and APACHE II scores, although they have some predictive value, still have limitations, including significant subjectivity and long-time consumption. Therefore, the search for new, objective biomarkers that reflect the severity of sepsis at an early stage is of substantial clinical importance (14). In recent years, the roles of fibroblast growth factor 9 (FGF9), Sestrin2, and 3-hydroxybutyrate dehydrogenase (HBDH) in various diseases have attracted increasing attention. FGF9 is a multifunctional growth factor that participates in processes such as cell proliferation, differentiation and migration. Studies (15–17) have shown that it plays a vital role in inflammatory responses. Sestrin2 is a stress-induced protein with functions including antioxidation, anti-apoptosis, and metabolic regulation. HBDH is a key enzyme in ketone body metabolism, and changes in its activity may reflect disturbances in energy metabolism in patients with sepsis. Preliminary research (18) suggests that the incidence and progression of sepsis may be correlated with levels of FGF9, Sestrin2, and HBDH, but the relationship between these factors and sepsis severity remains unclear.

This study detected and analysed serum levels of FGF9, Sestrin2, and HBDH in patients with sepsis and explored their relationships with disease severity and clinical outcomes.

Materials and Methods

General information and grouping

A retrospective analysis of 125 sepsis patients admitted to Taikang Xianlin Drum Tower Hospital and Chongqing University Central Hospital between May 2022 and May 2025 was conducted. The patients were divided into 75 cases in the sepsis group and 50 in the septic shock group based on illness severity, in accordance with the third definition of sepsis and septic shock, which is the international consensus standard. Based on clinical outcomes, patients were divided into a death group (103 cases) and a survival group (22 cases). The general patient data across groups were comparable and did not differ significantly ($P>0.05$).

Inclusion and exclusion criteria

Inclusion criteria: (1) It complies with the diagnostic criteria stipulated in the »Expert Consensus on Early Prevention and Blockade of Sepsis in Emergency Departments of China«; (2) Complete clinical data; (3) Clear consciousness and mind, with normal language communication skills.

Exclusion criteria: (1) Death within 24 hours of hospitalisation; (2) Long-term use of immunosuppressants for treatment; (3) Suffering from malignant tumours; (4) Combined with end-stage renal disease; (5) Combined with haematological and autoimmune diseases; (6) During pregnancy or lactation.

Detection of serum FGF9, Sestrin2 and HBDH levels

Five mL of the patient's fasting elbow venous blood was collected in the morning. The operation was carried out at 4 °C using a centrifuge (15 min, 3,500 r/min, 5 cm radius). The supernatant was separated and stored at -80 °C for future use. Serum levels of FGF9, Sestrin2, and HBDH were measured by enzyme-linked immunosorbent assay. Sample Wells, standard Wells and blank Wells were designed in the microplate. The sample Wells were filled with 50 µL of the test sample, and then 50 µL of FGF9, Sestrin2 and HBDH standards of different concentrations were added to the standard Wells. Add 50 µL of HRP to each well and incubate at room temperature for 1 hour. Then add washing buffer and wash 5 times. Incubate each well for 15 minutes with 50 µL of substrates A and B at 37 °C. With an enzyme-linked immunosorbent assay (ELISA) reader, add the stop solution and measure the standard Wells' absorbance value at 450 nm. HBDH, FGF9, and Sestrin2 levels were found.

Data collection

Conduct statistics on patient data

General information: Age, gender, body mass index, diabetes, hypertension, smoking, site of infection (urinary system, lungs, others).

Biochemical indicators

Acute Physiology and Chronic Health Evaluation II (APACHE II) score, serum creatinine, procalcitonin, white blood cell count, neutrophil count, platelet count, and sequential organ failure assessment (SOFA) score.

Observation indicators

The levels of serum FGF9, Sestrin2 and HBDH in patients of the sepsis group, septic shock group, survival group and death group. Analyse the correlation between serum FGF9, Sestrin2, HBDH and the severity of sepsis. Analyse the elements that affect sepsis patients' prognosis and their prognostic value for such patients' outcomes.

Statistical analysis

Data from the study were analysed using SPSS 20.0. The mean $\pm$ standard deviation ($\bar{x} \pm s$) was used for the measurement data. Analysis of variance was used to compare results across many groups, whereas the t-test was used to compare two groups. While analysis of variance was employed for comparisons among many groups, the t-test was used for comparisons between two groups. The χ^2 test was used to compare groups, and counts were presented as cases or percentages (%). The correlation was examined using the Spearman correlation coefficient model. Factors affecting the prognosis of sepsis patients were examined using multivariate logistic regression. Sensitivity, specificity, confidence intervals, and the area under the receiver operating characteristic (ROC) curve were used to assess the predictive value of FGF9, Sestrin2, and HBDH for sepsis prognosis.

Results

Serum levels of FGF9, Sestrin2, and HBDH were compared between the two patient groups

The serum FGF9 level of patients in the septic shock group was significantly lower than that in the sepsis group, while the levels of Sestrin2 and HBDH were significantly higher than those in the sepsis group, suggesting that during the progression of sepsis to septic shock, the FGF9 level decreased, while

Table I Serum FGF9, Sestrin2, and HBDH levels between two groups of sepsis patients ($\bar{x} \pm s$).

Group	Number of cases	FGF9 (pg/mL)	Sestrin2 (ng/mL)	HBDH (U/L)
Sepsis group	75	145.36 $\pm$ 23.68	8.36 $\pm$ 0.93	166.25 $\pm$ 24.85
Septic shock group	50	22.41 $\pm$ 21.45	15.75 $\pm$ 2.34	232.14 $\pm$ 34.77
t value		5.509	24.626	12.356
P value		<0.001	<0.001	<0.001

Table II Serum FGF9, Sestrin2, and HBDH levels in patients with sepsis with different prognoses ($\bar{x} \pm s$).

Group	Number of cases	FGF9 (pg/mL)	Sestrin2 (ng/mL)	HBDH (U/L)
Survival group	22	133.25 $\pm$ 22.14	12.42 $\pm$ 2.33	204.25 $\pm$ 32.18
Death group	103	112.05 $\pm$ 20.61	19.25 $\pm$ 2.85	261.25 $\pm$ 37.25
t value		4.323	10.505	6.661
P value		0.001	<0.001	<0.001

Table III Correlation between serum FGF9, Sestrin2, HBDH and the severity of sepsis.

Indicator	Severity	
	r value	P value
FGF9	-0.851	<0.001
Sestrin2	0.625	0.004
HBDH	0.733	<0.001

the levels of Sestrin2 and HBDH increased. The death group's serum FGF9 levels were likewise noticeably lower than those of the survival group, according to an additional study, while the levels of Sestrin2 and HBDH were significantly higher than those in the survival group, indicating that the levels of FGF9, Sestrin2 and HBDH are closely related to the prognosis of patients with sepsis.

The further reduction of FGF9 and the further increase of Sestrin2 and HBDH in patients of septic shock and death group may indicate disease deterioration and poor prognosis. Therefore, the differences in serum FGF9, Sestrin2 and HBDH levels may reflect the severity of the condition and prognostic risk in patients with sepsis.

The septic shock group had lower FGF9 levels than the sepsis group, while Sestrin2 and HBDH levels were higher (Table I).

Serum FGF9, Sestrin2 and HBDH levels in patients with different prognoses

Patients in the death group had lower levels of FGF9 than those in the survival group, while the Sestrin2 and HBDH levels were higher. According to Table II, the differences were statistically significant ($P < 0.05$). Patients in the death group had much lower serum FGF9 levels than those in the survival group, although they had significantly greater levels of Sestrin2 and HBDH. This finding suggests that serum levels of FGF9, Sestrin2, and HBDH are closely associated with the prognosis of patients with sepsis. Lower FGF9 levels and higher Sestrin2 and HBDH levels may indicate a poor prognosis for patients and an increased risk of death.

The correlation between serum FGF9, Sestrin2 and HBDH and the severity of sepsis

There is a strong correlation between sepsis severity and serum levels of FGF9, Sestrin2, and HBDH. The degree of sepsis is inversely correlated with FGF9 levels: as sepsis worsens, FGF9 levels gradually decrease. A comparison between the sepsis and septic shock groups further supported this pattern. Compared with the sepsis group, the FGF9 level in the septic shock group was noticeably lower, while the Sestrin2 and HBDH levels were significantly higher than those in the sepsis group.

The severity of the disease was taken as a categorical variable. A correlation analysis was conducted with sepsis as 1 and septic shock as 2. FGF9 was negatively correlated with the severity of sepsis ($P < 0.05$), while Sestrin2 and HBDH were positively correlated with the severity of sepsis ($P < 0.05$) (Table III).

Table IV Factors influencing the prognosis of sepsis patients with univariate analysis.

Data	Survival group (n=22)	Death group (n=103)	t/F/ χ^2 value	P value
Gender [Example (%)]			0.292	0.589
Male	11 (50.00)	58 (56.31)		
Female	11 (50.00)	45 (43.69)		
Age (Years, $\bar{x}\pm s$)	65.25 $\pm$ 3.58	65.31 $\pm$ 3.60	0.071	0.944
Body mass index (kg/m ² , $\bar{x}\pm s$)	22.25 $\pm$ 4.11	22.21 $\pm$ 4.08	0.042	0.967
Smoking [Cases (%)]			1.231	0.267
Yes	12 (54.55)	69 (66.99)		
No	10 (45.45)	34 (33.01)		
Diabetes [Cases (%)]			2.894	0.089
Yes	8 (36.36)	58 (56.31)		
No	14 (63.64)	45 (43.69)		
Hypertension [Cases (%)]			0.458	0.498
Yes	10 (45.45)	55 (53.40)		
No	12 (54.55)	48 (46.60)		
Infection site [Cases (%)]			0.303	0.762
Urinary system	8 (36.36)	42 (40.78)		
Lung	7 (31.82)	30 (29.12)		
Others	7 (31.82)	31 (30.10)		
SOFA score (Points, $\bar{x}\pm s$)	5.36 $\pm$ 0.64	11.25 $\pm$ 2.48	1.029	<0.001
APACHE II score (Points, $\bar{x}\pm s$)	13.12 $\pm$ 2.44	19.25 $\pm$ 2.85	9.374	<0.001
Procalcitonin (ng/mL, $\bar{x}\pm s$)	2.36 $\pm$ 0.34	12.52 $\pm$ 3.44	13.795	<0.001
White blood cell count ($\times 10^9/L$, $\bar{x}\pm s$)	8.12 $\pm$ 0.93	14.12 $\pm$ 2.38	11.606	<0.001
Neutrophil count ($\times 10^9/L$, $\bar{x}\pm s$)	70.36 $\pm$ 8.33	88.25 $\pm$ 9.27	8.355	<0.001
Platelet count ($\times 10^9/L$, $\bar{x}\pm s$)	194.36 $\pm$ 28.41	142.23 $\pm$ 23.22	9.177	<0.001
Serum creatinine ($\mu\text{mol/L}$, $\bar{x}\pm s$)	85.14 $\pm$ 9.23	91.25 $\pm$ 10.11	2.611	0.010

Univariate investigation of the variables affecting sepsis patients' prognosis

Regarding gender, age, body mass index, smoking, diabetes, hypertension, or infection site, there were no statistically significant differences between the two groups ($P>0.05$). Compared with the survival group, the SOFA score, APACHE II score, procalcitonin, Serum creatinine, neutrophil count, and white blood cell count were all greater in the death group, while the platelet count was lower (Table IV).

Multivariate logistic regression analysis was used to look at the factors influencing the prognosis of sepsis patients

The prognosis of sepsis patients was considered the dependent variable, and factors with $P<0.05$ in

the univariate analysis were selected as independent variables for assignment (survival = 0; death = 1). A logistic regression analysis with many variables was then performed. According to multivariate results, serum creatinine, procalcitonin, white blood cell, neutrophil, and platelet counts, FGF9, Sestrin2, HBDH, APACHE II score, SOFA score, and APACHE score are risk variables influencing the prognosis of sepsis patients ($P<0.05$) (Table V).

The prognostic value of FGF9, Sestrin2, and HBDH for the prognosis of sepsis patients was examined using a ROC curve

The area under the curve of the effect of individual detection of FGF9, Sestrin2 and HBDH in predicting the prognosis of patients with sepsis. The AUC

Table V Multivariate logistic regression analysis of factors influencing the prognosis of patients with sepsis.

Factor	β value	SE value	Wald χ^2 value	OR value	95% CI	P value
SOFA score	1.859	0.621	8.961	6.417	5.175~7.659	0.005
APACHE II score	1.215	0.314	15.873	3.494	2.866~4.122	<0.001
Procalcitonin	1.452	0.485	8.963	4.272	3.302~5.242	0.004
White blood cell count	1.332	0.214	38.742	3.7893	.361~4.217	<0.001
Neutrophil count	1.251	0.332	14.198	3.494	2.830~4.158	<0.001
Platelet count	0.332	0.125	7.054	1.394	1.144~1.644	0.008
Serum creatinine	1.458	0.221	43.524	4.297	3.855~4.739	<0.001
FGF9	0.856	0.214	16.000	2.354	1.926~2.782	<0.001
Sestrin2	1.552	0.321	23.376	4.721	4.079~5.363	<0.001
HBDH	1.052	0.336	9.803	2.863	2.191~3.535	<0.001

Table VI ROC curve analysis of the predictive value of FGF9, Sestrin2, and HBDH for the prognosis of patients with sepsis.

Project	AUC sensitivity (%)	Specificity (%)	Accuracy (%)	95%CI	P value
FGF9	0.71879.61 (82/103)	68.18 (15/22)	75.20 (94/125)	0.572~0.864	0.001
Sestrin2	0.7647.67 (80/103)	81.82 (18/22)	78.40 (98/125)	0.643~0.885	0.001
HBDH	0.66982.52 (85/103)	63.64 (14/22)	79.20 (99/125)	0.510~0.829	0.002
Joint testing	0.77195.15 (98/103)	59.09 (13/22)	88.80 (111/125)	0.641~0.902	0.001




Figure 1 ROC curve analysis was used to predict the prognosis of patients with sepsis by FGF9, Sestrin2 and HBDH.

values were 0.718, 0.764, and 0.669, respectively. When FGF9, Sestrin2, and HBDH were detected together, the AUC was 0.771, all of which were higher than those of the individual detections of FGF9, Sestrin2, and HBDH, and had good predictive value ($P < 0.05$) (Table VI and Figure 1).

Discussion

A systemic inflammatory illness known as sepsis develops when the body becomes infected with harmful bacteria (19–21). It can affect multiple organs. As the disease progresses, septic shock may occur, causing a drop in blood pressure in patients, damaging lung, liver and kidney functions, and threatening the patient's life. The clinical assessment of sepsis prognosis primarily uses the SOFA and APACHE II scores (22). However, this scoring process is complex and easily influenced by subjective factors, thereby reducing prediction accuracy. Consequently, it is essential to look for signs associated with sepsis, assess its development and prognosis accurately, determine the severity of the disease, predict the clinical prognosis, and carry out timely treatment interventions (23–25).

FGF9 is a polypeptide growth factor with a wide range of biological functions in clinical settings. It can participate in various biological processes, promote cell development, and facilitate tissue repair. When its expression level is abnormal, it can contribute to the development of many diseases. FGF9 can promote lipid accumulation in cells and regulate liver lipid metabolism through autocrine signalling. Moreover, FGF9 expression can affect the body's inflammatory response (26).

After FGF9 activates the phosphatidylinositol-3-kinase serine protein kinase pathway, it can alleviate the inflammatory response and inhibit the development of diseases. In patients with septic shock, FGF9 expression is relatively low. The level of FGF9 gradually decreases as disease severity increases (27–29). Sestrin2 is an oxidative stress-inducing protein and a key molecule in the antioxidant system. Moreover, Sestrin2 can promote the phosphorylation of adenosine monophosphate-activated protein kinase, increase hydrogen peroxide levels, inhibit reactive oxygen species expression, and reduce oxidative stress-induced cell damage (30). After the body undergoes hypoxia and oxidative stress, Sestrin2 expression can increase, exerting a protective effect. Relevant studies have shown that in patients with sepsis, Sestrin2 has a protective effect, inhibiting its

expression and increasing sepsis mortality. The possible reason is that Sestrin2 levels increase in septic shock, which may be driven by an excessive inflammatory response and increased oxidative stress, and this is an endogenous protective effect (31).

HBDH is widely distributed throughout the body. After septic shock occurs, it can alter hemodynamics and cause microcirculatory disorders, leading to myocardial ischemia, diffuse swelling, and myocardial cell disintegration and damage. Clinical studies (32–34) have shown that after myocardial cell injury, the contractile protein myosin can be involved, reducing myocardial contractility, causing myocardial cell disintegration, and promoting the release of HBDH. Moreover, abnormal HBDH expression can affect myocardial cells in patients, leading to myocardial ischemia and injury and a poor prognosis.

The ROC curve shows that the combined detection of FGF9, Sestrin2, and HBDH has a sensitivity of 95.15%, a specificity of 59.09%, and an accuracy of 88.80% in predicting the prognosis of patients with sepsis, indicating high predictive value. It suggests that detecting FGF9, Sestrin2, and HBDH can predict clinical outcomes in patients with sepsis and has a relatively high practical value.

Conclusion

In patients with sepsis, FGF9 levels are relatively low, while Sestrin2 and HBDH levels are relatively high. As disease severity worsens, FGF9 levels decrease, while Sestrin2 and HBDH levels increase, suggesting a correlation with disease severity. Moreover, FGF9, Sestrin2 and HBDH are risk factors leading to the death of patients. Clinically, monitoring FGF9, Sestrin2, and HBDH can predict the prognosis of patients with sepsis and support early diagnosis and treatment, with substantial clinical value.

Funding

This work is supported by »Clinical study on the early prediction of community-acquired sepsis by HLA-DR combined with cytokines« [TKKYZX20241513].

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.

References

- Li A, Li XM, Song CG, Xiao X, Yao WM, Tian HS. Fibroblast growth factor 9 attenuates sepsis-induced fulminant hepatitis in mice. *Amino Acids* 2022 Jul; 54(7): 1069–81. doi: 10.1007/s00726-022-03143-7. Epub 2022 Mar 18. PMID: 35304640.
- Li Y, Wan TT, Li JX, Xiao X, Liu L, Li HH, Guo SB. ACE2 Rescues Sepsis-Associated Encephalopathy by Reducing Inflammation, Oxidative Stress, and Neuronal Apoptosis via the Nrf2/Sestrin2 Signaling Pathway. *Mol Neurobiol* 2024 Nov; 61(11): 8640–55. doi: 10.1007/s12035-024-04063-1. Epub 2024 Mar 27. PMID: 38532242.
- Tian W, Song P, Zang J, Zhao J, Liu Y, Wang C, Fang H, Wang H, Zhao Y, Liu X, Gao Y, Cao L. Tanshinone IIA, a component of *Salvia miltiorrhiza* Bunge, attenuated sepsis-induced liver injury via the SIRT1/Sestrin2/HO-1 signaling pathway. *J Ethnopharmacol* 2025 Jan 31; 340: 119169. doi: 10.1016/j.jep.2024.119169. Epub 2024 Nov 29. PMID: 39617088.
- Williams B, Zou L, Pittet JF, Chao W. Sepsis-Induced Coagulopathy: A Comprehensive Narrative Review of Pathophysiology, Clinical Presentation, Diagnosis, and Management Strategies. *Anesth Analg* 2024 Apr 1; 138(4): 696–711. doi: 10.1213/ANE.0000000000006888. Epub 2024 Feb 7. PMID: 38324297; PMCID: PMC10916756.
- Legrand M, Bagshaw SM, Bhatraju PK, Bihorac A, Caniglia E, Khanna AK, Kellum JA, Koyner J, Harhay MO, Zampieri FG, Zarbock A, Chung K, Liu K, Mehta R, Pickkers P, Ryan A, Bernholz J, Dember L, Gallagher M, Rossignol P, Ostermann M. Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials. *Crit Care* 2024 Mar 21; 28(1): 92. doi: 10.1186/s13054-024-04877-4. PMID: 38515121; PMCID: PMC10958912.
- Legrand M, Khanna AK, Ostermann M, Kotani Y, Ferrer R, Girardis M, Leone M, DePascale G, Pickkers P, Tissieres P, Annoni F, Kotfis K, Landoni G, Zarbock A, Wieruszewski PM, De Backer D, Vincent JL, Bellomo R. The renin-angiotensin-aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II. *Crit Care* 2024 Nov 26; 28(1): 389. doi: 10.1186/s13054-024-05123-7. PMID: 39593182; PMCID: PMC11590289.
- Siwakoti S, Sah R, Singh RR, Khanal B. Clinical, Bacteriological Profile and Outcome of Neonatal Sepsis. *J Nepal Health Res Counc* 2023 Jul 20; 20(4): 967–72. doi: 10.33314/jnhrc.v20i4.4381. PMID: 37489686.
- Iyer S, Kennedy JN, Jentzer JC, Senussi MH, Seymour CW. Cardiac Function Before Sepsis and Clinical Outcomes. *JAMA* 2024 May 7; 331(17): 1496–9. doi: 10.1001/jama.2024.3917. PMID: 38587828; PMCID: PMC11002764.
- Cao Y, He L, Su Y, Luo J, Ding N. Triglyceride-glucose index and clinical outcomes in sepsis: A retrospective cohort study of MIMIC-IV. *J Cell Mol Med* 2024 Aug; 28(16): e70007. doi: 10.1111/jcmm.70007. PMID: 39198963; PMCID: PMC11358033.
- Bhavani SV, Spicer A, Sinha P, Malik A, Lopez-Espina C, Schmalz L, Watson GL, Bhargava A, Khan S, Urdiales D, Updike L, Dagan A, Davila H, Demarco C, Evans N, Gosai F, Iyer K, Kurtzman N, Palagiri AV, Sims M, Smith S, Syed A, Sarma D, Reddy B Jr, Verhoef PA, Churpek MM. Distinct immune profiles and clinical outcomes in sepsis subphenotypes based on temperature trajectories. *Intensive Care Med* 2024 Dec; 50(12): 2094–104. doi: 10.1007/s00134-024-07669-0. Epub 2024 Oct 9. PMID: 39382693.
- Ginestra JC, Coz Yataco AO, Dugar SP, Dettmer MR. Hospital-Onset Sepsis Warrants Expanded Investigation and Consideration as a Unique Clinical Entity. *Chest* 2024 Jun; 165(6): 1421–30. doi: 10.1016/j.chest.2024.01.028. Epub 2024 Jan 19. PMID: 38246522; PMCID: PMC11177099.
- Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. *International Journal of Bioprinting* 2024; 10(1): 1256. doi: 10.36922/ijb.1256.
- Miao S, Liu Y, Li M, Yan J. Clinical subtypes identification and feature recognition of sepsis leukocyte trajectories based on machine learning. *Sci Rep* 2025 Apr 10; 15(1): 12291. doi: 10.1038/s41598-025-96718-9. PMID: 40210965; PMCID: PMC11986166.
- Zöllner FG, Caroli A, Selby NM. Editorial for »Perfusion and T2 Relaxation Time as Predictors of Severity and Outcome in Sepsis-Associated Acute Kidney Injury: A Preclinical MRI Study«. *J Magn Reson Imaging* 2023 Dec; 58(6): 1964–5. doi: 10.1002/jmri.28696. Epub 2023 Mar 23. PMID: 36951531.
- Hong G, Ju H, Oh DK, Lee SY, Park MH, Lee H, Lim CM, Lee SI; Korean Sepsis Alliance (KSA) investigators. Clinical characteristics and prognostic factors of sepsis in patients with malignancy. *Sci Rep* 2025 Feb 27; 15(1): 7078. doi: 10.1038/s41598-025-87457-y. PMID: 40016348; PMCID: PMC11932214.
- Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. *Vaccines (Basel)* 2024 Feb 12; 12(2): 186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
- Marsh MC, Lin HM, Black J, Allen K, Weiner B, Ramilo O, Klammer B, Watson JR, Kasick R. Preterm and Term Infants Evaluated for Sepsis: Differences in Management and Clinical Outcomes. *Hosp Pediatr* 2023 Jun 1; 13(6): 544–54. doi: 10.1542/hpeds.2022-007050. PMID: 37222075.
- Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. *Heliyon* 2024 Mar 28; 10(7): e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
- DeMerle KM, Kennedy JN, Chang CH, Delucchi K, Huang DT, Kravitz MS, Shapiro NI, Yealy DM, Angus DC, Calfee CS, Seymour CW. Identification of a hyperinflammatory sepsis phenotype using protein biomarker and

- clinical data in the ProCESS randomised trial. *Sci Rep* 2024 Mar 14; 14(1): 6234. doi: 10.1038/s41598-024-55667-5. PMID: 38485953; PMCID: PMC10940677.
20. Yao RQ, Shen Z, Ma QM, Ling P, Wei CR, Zheng LY, Duan Y, Li W, Zhu F, Sun Y, Wu GS. Combination of transcriptional biomarkers and clinical parameters for early prediction of sepsis-induced acute respiratory distress syndrome. *Front Immunol* 2023 Jan 4; 13: 1084568. doi: 10.3389/fimmu.2022.1084568. PMID: 36685531; PMCID: PMC9846102.
 21. Kurul Ş, Beckers FLM, Vermeulen MJ, Suurland J, Hasbek JE, Ramakers CRB, Simons SHP, Reiss IKM, Taal HR. Inflammation, sepsis severity and neurodevelopmental outcomes of late-onset sepsis in preterm neonates. *Pediatr Res* 2023 Dec; 94(6): 2026–32. doi: 10.1038/s41390-023-02742-8. Epub 2023 Jul 19. PMID: 37468719.
 22. Guo Q, Li W, Wang J, Wang G, Deng Q, Lian H, Wang X. Construction and validation of a clinical prediction model for sepsis using peripheral perfusion index to predict in-hospital and 28-day mortality risk. *Sci Rep* 2024 Nov 5; 14(1): 26827. doi: 10.1038/s41598-024-78408-0. PMID: 39501076; PMCID: PMC11538300.
 23. Lu Y, Song L. Clinical Significance of Procalcitonin, Lactic Acid, and Endotoxin Testing for Children With Severe Pneumonia and Sepsis. *Altern Ther Health Med* 2023 Apr; 29(3): 218–23. PMID: 36795523.
 24. Safabakhsh M, Imani H, Shahinfar H, Mohammadpour M, Rohani P, Shab-Bidar S. Efficacy of dietary supplements on mortality and clinical outcomes in adults with sepsis and septic shock: A systematic review and network meta-analysis. *Clin Nutr* 2024 Jun; 43(6): 1299–307. doi: 10.1016/j.clnu.2024.03.030. Epub 2024 Apr 10. PMID: 38663051.
 25. Lyons PG, McEvoy CA, Hayes-Lattin B. Sepsis and acute respiratory failure in patients with cancer: how can we improve care and outcomes even further? *Curr Opin Crit Care* 2023 Oct 1; 29(5): 472–83. doi: 10.1097/MCC.0000000000001078. Epub 2023 Jul 28. PMID: 37641516; PMCID: PMC11142388.
 26. van der Vegt AH, Scott IA, Dermawan K, Schnetler RJ, Kalke VR, Lane PJ. Deployment of machine learning algorithms to predict sepsis: systematic review and application of the SALIENT clinical AI implementation framework. *J Am Med Inform Assoc* 2023 Jun 20; 30(7): 1349–61. doi: 10.1093/jamia/ocad075. PMID: 37172264; PMCID: PMC10280361.
 27. Zhao WT, Herrmann KH, Sibgatulin R, Nahardani A, Krämer M, Heitplatz B, van Marck V, Reuter S, Reichenbach JR, Hoerr V. Perfusion and T2 Relaxation Time as Predictors of Severity and Outcome in Sepsis-Associated Acute Kidney Injury: A Preclinical MRI Study. *J Magn Reson Imaging* 2023 Dec; 58(6): 1954–63. doi: 10.1002/jmri.28698. Epub 2023 Apr 7. Erratum in: *J Magn Reson Imaging* 2025 Jan; 61(1): 524. doi: 10.1002/jmri.29443. PMID: 37026419.
 28. Kam KQ, Chen T, Kadri SS, Lawandi A, Yek C, Walker M, Warner S, Fram D, Chen HC, Shappell CN, DelloStritto L, Jin R, Klompas M, Rhee C. Epidemiology and Outcomes of Antibiotic De-escalation in Patients With Suspected Sepsis in US Hospitals. *Clin Infect Dis* 2025 Feb 5; 80(1): 108–17. doi: 10.1093/cid/ciae591. PMID: 39657050; PMCID: PMC11797381.
 29. Pohl N, Bauer M, Pancaro C, Cassidy R, Engoren M. Characteristics and Outcomes of Obstetric Sepsis by Three Sets of Clinical Diagnostic Criteria: A Retrospective Study. *Am J Perinatol* 2024 May; 41(S 01): e3035–e3044. doi: 10.1055/a-2185-3931. Epub 2023 Oct 4. PMID: 37793431.
 30. Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. *Aging (Albany NY)* 2021 Apr 20; 13(8): 10833–52. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
 31. Chander S, Kumari R, Wang HY, Mohammed YN, Parkash O, Lohana S, Sorath F, Lohana AC, Sadarat F, Shiwani S. Effect of low vs. high vancomycin trough level on the clinical outcomes of adult patients with sepsis or gram-positive bacterial infections: a systematic review and meta-analysis. *BMC Infect Dis* 2024 Oct 7; 24(1): 1114. doi: 10.1186/s12879-024-09927-4. Erratum in: *BMC Infect Dis* 2025 Mar 17; 25(1): 371. doi: 10.1186/s12879-025-10745-5. PMID: 39375599; PMCID: PMC11457423.
 32. MacAllister SA, Fernandez AR, Smith MJ, Myers JB, Crowe RP. Prehospital Sepsis Recognition and Outcomes for Patients with Sepsis by Race and Ethnicity. *Prehosp Emerg Care* 2024; 28(7): 898–904. doi: 10.1080/10903127.2023.2294269. Epub 2023 Dec 22. PMID: 38095600.
 33. Moazen J, Zaniani FR, Kassani A, Akhondshushtari P, Ahmadi Z. Prognostic and clinical indicators of sepsis outcomes in hospitalised patients: a cross-sectional study. *BMC Infect Dis* 2025 Apr 21; 25(1): 567. doi: 10.1186/s12879-025-10796-8. PMID: 40259258; PMCID: PMC12010619.
 34. Blank JA, King JE, Grant JF, Tian S, Shrestha S, England P, Paje D, Taylor SP. Characteristics, clinical care, and outcomes of sepsis among patients boarding in the emergency department. *J Hosp Med* 2025 Apr; 20(4): 368–73. doi: 10.1002/jhm.13536. Epub 2024 Oct 27. PMID: 39462682; PMCID: PMC11963743

Received: September 11, 2025

Accepted: November 05, 2025